Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PKLR | P30613 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926772 | 0.83 | F2 (0.65) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL2874475 | 0.79 | F2 (0.56) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL7835980 | 0.77 | F2 (0.57) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL29391838 | 0.77 | LMNA (0.63) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL25642 | 0.77 | LMNA (0.63) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL758323 | 0.77 | ATM (0.66) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL1952494 | 0.76 | LMNA (0.68) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL30286769 | 0.76 | F2 (0.56) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL875072 | 0.76 | F2 (0.56) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL27629181 | 0.75 | LMNA (0.61) | F2PRSS1PRSS2PRSS3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | F2 614/4885PRSS1 842/4885PRSS2 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.